potassium citrate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
4519 866-84-2

Description:

MoleculeDescription

Synonyms:

  • potassium citrate anhydrous
  • potassium citrate
  • tripotassium citrate
A powder that dissolves in water, which is administered orally, and is used as a diuretic, expectorant, systemic alkalizer, and electrolyte replenisher.
  • Molecular weight: 306.39
  • Formula: C6H5K3O7
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA: 140.62
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
4 g O

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
April 30, 2021 EMA Advicenne S.A.
Aug. 30, 1985 FDA MISSION PHARMA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
General physical health deterioration 79.31 18.82 97 4843 355018 90268489
Nephrolithiasis 76.48 18.82 42 4898 49043 90574464
Multiple fractures 72.34 18.82 25 4915 9537 90613970
Haematochezia 64.61 18.82 43 4897 70870 90552637
Hypertonic bladder 60.21 18.82 18 4922 4330 90619177
Therapeutic drug monitoring analysis not performed 49.41 18.82 12 4928 1317 90622190
Dementia 41.56 18.82 22 4918 23839 90599668
Fall 41.45 18.82 85 4855 481725 90141782
Systemic infection 38.12 18.82 13 4927 4762 90618745
Product monitoring error 34.83 18.82 12 4928 4532 90618975
Anaemia 33.61 18.82 65 4875 352737 90270770
Dizziness 29.15 18.82 84 4856 589200 90034307
Product residue present 27.80 18.82 10 4930 4281 90619226
Dehydration 26.53 18.82 42 4898 194405 90429102
Nasal polypectomy 24.44 18.82 4 4936 56 90623451
Balance disorder 23.99 18.82 28 4912 97052 90526455
Renal tubular acidosis 21.24 18.82 7 4933 2308 90621199
Thrombocytopenia 20.50 18.82 39 4901 208686 90414821
Anaemia of malignant disease 19.91 18.82 5 4935 629 90622878
Faeces soft 19.23 18.82 9 4931 7502 90616005
Gait disturbance 18.93 18.82 43 4897 260453 90363054

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nephrolithiasis 87.56 20.94 49 3705 36781 42580800
General physical health deterioration 43.91 20.94 60 3694 151186 42466395
Calculus urinary 31.85 20.94 10 3744 1747 42615834
Product residue present 30.88 20.94 11 3743 2830 42614751
Regurgitation 30.88 20.94 10 3744 1930 42615651
Tracheal pain 30.60 20.94 5 3749 41 42617540
Nephrocalcinosis 29.91 20.94 8 3746 795 42616786
Vitamin B12 deficiency 28.30 20.94 12 3742 4910 42612671
Waist circumference increased 28.30 20.94 8 3746 976 42616605
Oropharyngeal discomfort 26.83 20.94 11 3743 4138 42613443
Atrioventricular block 26.14 20.94 14 3740 9601 42607980
Consciousness fluctuating 26.01 20.94 8 3746 1307 42616274
Respiratory tract haemorrhage 25.46 20.94 8 3746 1401 42616180
N-terminal prohormone brain natriuretic peptide increased 25.25 20.94 10 3744 3443 42614138
Systemic infection 24.43 20.94 11 3743 5194 42612387
Oesophageal ulcer 24.42 20.94 10 3744 3749 42613832
Pseudoporphyria 23.61 20.94 6 3748 488 42617093
Eye swelling 23.34 20.94 14 3740 11906 42605675
Interstitial granulomatous dermatitis 22.86 20.94 5 3749 212 42617369
Oedema peripheral 22.77 20.94 42 3712 136034 42481547
Dysuria 22.54 20.94 20 3734 31076 42586505
Product solubility abnormal 22.41 20.94 6 3748 598 42616983
Abdominal pain 21.53 20.94 50 3704 190421 42427160
Pain 21.13 20.94 58 3696 244790 42372791

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
General physical health deterioration 128.82 17.08 154 7652 425141 110156352
Nephrolithiasis 124.41 17.08 70 7736 66142 110515351
Multiple fractures 67.65 17.08 25 7781 8915 110572578
Systemic infection 61.80 17.08 24 7782 9795 110571698
Therapeutic drug monitoring analysis not performed 60.40 17.08 16 7790 1915 110579578
Hypertonic bladder 52.11 17.08 18 7788 5284 110576209
Product monitoring error 49.81 17.08 20 7786 8907 110572586
Dehydration 45.08 17.08 75 7731 279436 110302057
Haematochezia 43.58 17.08 47 7759 115477 110466016
Product residue present 41.15 17.08 14 7792 3927 110577566
Anaemia 38.93 17.08 105 7701 546981 110034512
Nephrocalcinosis 38.12 17.08 11 7795 1803 110579690
Fall 36.29 17.08 109 7697 603373 109978120
Dysuria 32.91 17.08 30 7776 60201 110521292
Cardiac failure chronic 32.59 17.08 17 7789 13794 110567699
Oedema peripheral 30.65 17.08 70 7736 328590 110252903
Dementia 30.56 17.08 22 7784 31651 110549842
Tracheal pain 30.54 17.08 5 7801 53 110581440
Dizziness 30.32 17.08 113 7693 698080 109883413
Regurgitation 27.30 17.08 10 7796 3475 110578018
Localised infection 26.62 17.08 23 7783 43025 110538468
Renal impairment 25.70 17.08 47 7759 188398 110393095
Vitamin B12 deficiency 25.52 17.08 13 7793 10042 110571451
Waist circumference increased 25.27 17.08 8 7798 1793 110579700
Chronic kidney disease 25.25 17.08 29 7777 76262 110505231
N-terminal prohormone brain natriuretic peptide increased 25.05 17.08 11 7795 6110 110575383
Respiratory tract haemorrhage 24.39 17.08 8 7798 2006 110579487
Atrioventricular block 24.20 17.08 15 7791 16862 110564631
Interstitial granulomatous dermatitis 22.45 17.08 5 7801 289 110581204
Cardiac failure 22.13 17.08 44 7762 187582 110393911
Pseudoporphyria 22.03 17.08 6 7800 797 110580696
Aortic stenosis 19.73 17.08 12 7794 13047 110568446
Oropharyngeal discomfort 19.59 17.08 11 7795 10316 110571177
Oesophageal ulcer 19.35 17.08 10 7796 7954 110573539
Electrocardiogram abnormal 18.06 17.08 13 7793 18696 110562797
Renal tubular acidosis 17.77 17.08 8 7798 4707 110576786
Tachycardia 17.59 17.08 45 7761 226600 110354893
Calculus urinary 17.37 17.08 7 7799 3145 110578348

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A12BA02 ALIMENTARY TRACT AND METABOLISM
MINERAL SUPPLEMENTS
POTASSIUM
Potassium
FDA MoA N0000009986 Alkalinizing Activity
FDA EPC N0000175896 Metabolic Alkalinizer
MeSH PA D004232 Diuretics
MeSH PA D005100 Expectorants
MeSH PA D019141 Respiratory System Agents
MeSH PA D045283 Natriuretic Agents
CHEBI has role CHEBI:35498 diuretics

Related Drugs by ATC class:

A12BA Potassium 4 drugs
potassium bitartratepotassium chloridepotassium gluconatepotassium hydrogencarbonate

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Renal tubular acidosis indication 1776003 DOID:14219
Hypokalemia indication 43339004
Uric acid renal calculus indication 274401005
Calcium renal calculus indication 427649000
Calcium Phosphate Renal Calculi indication
Calcium Oxalate Renal Calculi indication
Hypokalemia Prevention indication
Cystinuria off-label use 85020001 DOID:9266
Cystine Renal Calculi off-label use
Metabolic alkalosis contraindication 1388004
Anuria contraindication 2472002 DOID:2983
Hypocalcemia contraindication 5291005
Peptic ulcer contraindication 13200003 DOID:750
Hyperkalemia contraindication 14140009
Pulmonary edema contraindication 19242006 DOID:11396
Myocardial infarction contraindication 22298006 DOID:5844
Ventricular tachycardia contraindication 25569003
Complete atrioventricular block contraindication 27885002
Dehydration contraindication 34095006
Hyperthyroidism contraindication 34486009 DOID:7998
Acute hepatitis contraindication 37871000
Hypertensive disorder contraindication 38341003 DOID:10763
Hypernatremia contraindication 39355002
Gastrointestinal ulcer contraindication 40845000
Chronic heart failure contraindication 48447003
Bradycardia contraindication 48867003
Acidosis contraindication 51387008
Congenital myotonia, autosomal dominant form contraindication 57938005
Acute nephropathy contraindication 58574008
Metabolic acidosis contraindication 59455009
Diarrhea contraindication 62315008
Arterial thrombosis contraindication 65198009
Arteriosclerotic vascular disease contraindication 72092001
Hyperchloremia contraindication 74450001
Gastrointestinal hemorrhage contraindication 74474003
Third degree burn injury contraindication 80247002
Oliguria contraindication 83128009
Kidney disease contraindication 90708001 DOID:557
Gastrointestinal obstruction contraindication 126765001
Partial atrioventricular block contraindication 195039008
Acute pancreatitis contraindication 197456007 DOID:2913
Impaired renal function disorder contraindication 197663003
Myocardial dysfunction contraindication 233928007
Gastroparesis contraindication 235675006
Chronic diarrhea contraindication 236071009
Hyporeninemic hypoaldosteronism contraindication 236464008
Rhabdomyolysis contraindication 240131006
Esophageal dysmotility contraindication 266434009 DOID:9192
Benign prostatic hyperplasia contraindication 266569009
Peripheral edema contraindication 271809000
Familial hyperkalemic periodic paralysis contraindication 304737009 DOID:14451
Primary adrenocortical insufficiency contraindication 373662000
Adrenal cortical hypofunction contraindication 386584007 DOID:10493
Hypoxia contraindication 389086002
Disorder of coronary artery contraindication 414024009
Ketoacidosis in diabetes mellitus contraindication 420422005 DOID:1837
Hypertensive urgency contraindication 443482000
Azotemia contraindication 445009001
Severe dehydration contraindication 450316000
Genitourinary Tract Infections contraindication
Esophageal Compression contraindication




🐶 Veterinary Drug Use

SpeciesUseRelation
Cattle Dehydration associated with diarrhea Indication
Cattle Early treatment of scouring Indication
Cattle Treatment following intravenous fluid therapy Indication

🐶 Veterinary products

ProductApplicantIngredients
Re-Sorb, Vytrate Zoetis Inc. 6

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
D05578 KEGG_DRUG
6100-05-6 SECONDARY_CAS_RN
4017519 VANDF
CHEBI:64733 CHEBI
CHEMBL3989822 ChEMBL_ID
CHEMBL1200458 ChEMBL_ID
DB09125 DRUGBANK_ID
EE90ONI6FF UNII
1374802 RXNORM
35532 MMSL
5328 MMSL
72288 MMSL
NOCODE MMSL
d01423 MMSL
000746 NDDF
000766 NDDF
002330 NDDF
387450001 SNOMEDCT_US
78542000 SNOMEDCT_US
C0137996 UMLSCUI
D019357 MESH_DESCRIPTOR_UI
2735208 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Potassium Citrate and Citric Acid HUMAN PRESCRIPTION DRUG LABEL 2 0121-0676 SOLUTION 1100 mg ORAL unapproved drug other 12 sections
TRICITRATES HUMAN PRESCRIPTION DRUG LABEL 3 0121-0677 SOLUTION 550 mg ORAL unapproved drug other 12 sections
UROCIT-K HUMAN PRESCRIPTION DRUG LABEL 1 0178-0600 TABLET, EXTENDED RELEASE 5 meq ORAL NDA 16 sections
UROCIT-K HUMAN PRESCRIPTION DRUG LABEL 1 0178-0610 TABLET, EXTENDED RELEASE 10 meq ORAL NDA 16 sections
UROCIT-K HUMAN PRESCRIPTION DRUG LABEL 1 0178-0615 TABLET, EXTENDED RELEASE 15 meq ORAL NDA 16 sections
Potassium Citrate HUMAN PRESCRIPTION DRUG LABEL 1 0245-0070 TABLET 5 meq ORAL NDA 22 sections
Potassium Citrate HUMAN PRESCRIPTION DRUG LABEL 1 0245-0071 TABLET 10 meq ORAL NDA 22 sections
Potassium Citrate HUMAN PRESCRIPTION DRUG LABEL 1 0591-2682 TABLET, EXTENDED RELEASE 5 meq ORAL ANDA 19 sections
Potassium Citrate HUMAN PRESCRIPTION DRUG LABEL 1 0591-2729 TABLET, EXTENDED RELEASE 10 meq ORAL ANDA 19 sections
Potassium Citrate HUMAN PRESCRIPTION DRUG LABEL 1 0591-2742 TABLET, EXTENDED RELEASE 15 meq ORAL ANDA 19 sections
POTASSIUM CITRATE Human Prescription Drug Label 1 16571-864 TABLET, EXTENDED RELEASE 540 mg ORAL ANDA 19 sections
POTASSIUM CITRATE Human Prescription Drug Label 1 16571-865 TABLET, EXTENDED RELEASE 1080 mg ORAL ANDA 19 sections
TRICITRATES HUMAN PRESCRIPTION DRUG LABEL 3 17856-0677 SOLUTION 550 mg ORAL UNAPPROVED DRUG OTHER 12 sections
POTASSIUM CITRATE HUMAN PRESCRIPTION DRUG LABEL 1 31722-129 TABLET, EXTENDED RELEASE 5 meq ORAL ANDA 16 sections
POTASSIUM CITRATE HUMAN PRESCRIPTION DRUG LABEL 1 31722-130 TABLET, EXTENDED RELEASE 10 meq ORAL ANDA 16 sections
POTASSIUM CITRATE HUMAN PRESCRIPTION DRUG LABEL 1 31722-132 TABLET, EXTENDED RELEASE 15 meq ORAL ANDA 16 sections
POTASSIUM CITRATEEXTENDED RELEASE HUMAN PRESCRIPTION DRUG LABEL 1 42543-406 TABLET 5 meq ORAL ANDA 19 sections
POTASSIUM CITRATEEXTENDED RELEASE HUMAN PRESCRIPTION DRUG LABEL 1 42543-407 TABLET 10 meq ORAL ANDA 19 sections
POTASSIUM CITRATEEXTENDED RELEASE HUMAN PRESCRIPTION DRUG LABEL 1 42543-408 TABLET 15 meq ORAL ANDA 19 sections
POTASSIUM CITRATE HUMAN PRESCRIPTION DRUG LABEL 1 43602-399 TABLET, EXTENDED RELEASE 5 meq ORAL ANDA 17 sections
POTASSIUM CITRATE HUMAN PRESCRIPTION DRUG LABEL 1 43602-400 TABLET, EXTENDED RELEASE 10 meq ORAL ANDA 17 sections
POTASSIUM CITRATE HUMAN PRESCRIPTION DRUG LABEL 1 43602-401 TABLET, EXTENDED RELEASE 15 meq ORAL ANDA 17 sections
Potassium Citrate HUMAN PRESCRIPTION DRUG LABEL 1 44523-410 TABLET 10 meq ORAL NDA authorized generic 20 sections
Potassium Citrate HUMAN PRESCRIPTION DRUG LABEL 1 44523-415 TABLET 15 meq ORAL NDA authorized generic 20 sections
Potassium Citrate HUMAN PRESCRIPTION DRUG LABEL 1 51407-449 TABLET, EXTENDED RELEASE 5 meq ORAL ANDA 20 sections
Potassium Citrate HUMAN PRESCRIPTION DRUG LABEL 1 51407-450 TABLET, EXTENDED RELEASE 10 meq ORAL ANDA 20 sections
Potassium Citrate HUMAN PRESCRIPTION DRUG LABEL 1 51407-451 TABLET, EXTENDED RELEASE 15 meq ORAL ANDA 20 sections
UROCIT-K HUMAN PRESCRIPTION DRUG LABEL 1 54868-4779 TABLET, EXTENDED RELEASE 10 meq ORAL NDA 23 sections
Potassium Citrate HUMAN PRESCRIPTION DRUG LABEL 1 54868-5644 TABLET, EXTENDED RELEASE 1080 mg ORAL ANDA 11 sections
UROCIT-K HUMAN PRESCRIPTION DRUG LABEL 1 54868-6176 TABLET, EXTENDED RELEASE 15 meq ORAL NDA 23 sections